First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy

Table 3 Result of chemotherapy response of each regimen

	Elderly group: 65-74 yr			Very elderly group: 75+ yr
	Gemcitabine mono, n = 25	GA and FOLFIRINOX, n = 25	P value	Gemcitabine mono, n = 10	GA and FOLFIRINOX, n = 10	P value
Chemo response1			0.069			0.355
PR	0 (0.0)	3 (12.5)		0 (0.0)	0 (0.0)
SD	10 (67.7)	16 (66.7)		6 (60.0)	8 (80.0)
PD	7 (41.2)	5 (20.8)		4 (40.0)	2 (20.0)
DCR, PR + SD	10 (58.8)	19 (79.2)	0.166	6 (60.0)	8 (80.0)	0.355
Tumor burden change, %	11.4 ± 22.8	-4.1 ± 23.1	0.049a	7.0 (-9.1-39.7)	3.5 (-5.9-13.4)	0.633
Tumor burden change, % in patients with PR or SD	1.1 ± 7.1	-10.7 ± 19.5	0.091	-7.0 (-23.9-8.6)	0.0 (-7.7-10.0)	0.366
Dose reduction	10 (40.0)	18 (72.0)	0.022a	7 (70.0)	9 (90.0)	0.288
Delivery dose	89.6 ± 12.4	84.4 ± 15.3	0.196	81.9 (73.1-93.4)	67.7 (64.6-84.6)	0.218
Total over 80% dose	17 (68.0)	15 (60.0)	0.565	6 (60.0)	4 (40.0)	0.398
Chemotherapy days	56.0 (29.7-82.3)	112.0 (43.5-180.5)	0.001a	98.0 (0.0-206.5)	112.0 (27.0-197.0)	0.790
Progression-free survival	62.0 (55.3-125.4)	206.0 (158.1-300.5)	0.000a	147.0 (86.4-263.0)	174.0 (94.6-270.4)	0.796
Overall survival	102.0 (75.6-155.1)	302.0 (215.9-388.4)	0.000a	227.0 (108.9-342.1)	211.0 (125.3-314.3)	0.739
2nd chemotherapy	3 (12.0)	12 (48.0)	0.005a	1 (10.0)	3 (30.0)	0.288
TS-1	1 (4.0)	6 (24.0)		1 (10.0)	2 (20.0)
Gemcitabine mono	0 (0.0)	4 (16.0)		0 (0.0)	1 (10.0)
GA	0 (0.0)	1 (4.0)		0 (0.0)	0 (0.0)
FOLFIRINOX	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)
Onivyde	1 (4.0)	0 (0.0)		0 (0.0)	0 (0.0)
5-FU base	1 (4.0)	1 (4.0)		0 (0.0)	0 (0.0)
2nd chemotherapy PFS in d	86.0 (23.7-125.6)	83.0 (45.5-123.4)	0.572	75 (N/A)	74 (-17.5-136.9)	0.999

Data presented as: n (%); Mean ± SD; Median: 95% confidence interval;

¹Includes only patients who survive over 60 d.

^aP < 0.05. 5-FU: 5-fluorouracil; DCR: Disease control rate; GA: Gemcitabine plus nab-paclitaxel; PD: Progressive disease; PFS: Progression-free survival; PR: Partial response; SD: Stable disease; TS-1: Titanium silicate-1.